Cargando…

Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study

BACKGROUND: Multiple sclerosis (MS) has a highly heterogenic course making prediction of long term outcome very difficult. OBJECTIVE: The objective was to evaluate current and identify additional clinical factors that are linked to long term outcome of relapsing-remitting MS assessed by disability s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bsteh, Gabriel, Ehling, Rainer, Lutterotti, Andreas, Hegen, Harald, Di Pauli, Franziska, Auer, Michael, Deisenhammer, Florian, Reindl, Markus, Berger, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938610/ https://www.ncbi.nlm.nih.gov/pubmed/27391947 http://dx.doi.org/10.1371/journal.pone.0158978

Ejemplares similares

Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study
por: Wurth, Sebastian, et al.
Publicado: (2017)

Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis—The PaSiMS II study
por: Bsteh, Gabriel, et al.
Publicado: (2017)

Fibrinogen is not elevated in the cerebrospinal fluid of patients with multiple sclerosis
por: Ehling, Rainer, et al.
Publicado: (2011)

Multiple sclerosis and COVID‐19: How many are at risk?
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Cerebrospinal Fluid Findings in 541 Patients With Clinically Isolated Syndrome and Multiple Sclerosis: A Monocentric Study
por: Berek, Klaus, et al.
Publicado: (2021)

Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study
por: Hegen, Harald, et al.
Publicado: (2017)

Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Estimating Risk of Multiple Sclerosis Disease Reactivation in Pregnancy and Postpartum: The VIPRiMS Score
por: Bsteh, Gabriel, et al.
Publicado: (2022)

Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis
por: Hegen, Harald, et al.
Publicado: (2018)

Smoking is not associated with higher prevalence of JC virus in MS patients
por: Auer, Michael, et al.
Publicado: (2018)

Influence of physical activity on serum vitamin D levels in people with multiple sclerosis
por: Bauer, Angelika, et al.
Publicado: (2020)

Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years
por: Auer, Michael, et al.
Publicado: (2021)

Conversion and reversion of anti‐John Cunningham virus antibody serostatus: A prospective study
por: Auer, Michael, et al.
Publicado: (2019)

Inner nuclear layer and olfactory threshold are interlinked and reflect inflammatory activity in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Cerebrospinal Fluid B Cells Correlate with Early Brain Inflammation in Multiple Sclerosis
por: Kuenz, Bettina, et al.
Publicado: (2008)

Serum hepcidin levels in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2019)

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and Varicella Zoster Virus Infection - Frequency of an Association
por: Di Pauli, Franziska, et al.
Publicado: (2021)

Serum neurofilament light levels correlate with change of olfactory function in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2019)

SARS-CoV2 infection as a potential trigger for severe relapse in a patient with multiple sclerosis who stopped disease modifying treatment due to COVID-19 pandemic
por: Auer, Michael, et al.
Publicado: (2021)

Kappa-Free Light Chains in CSF Predict Early Multiple Sclerosis Disease Activity
por: Berek, Klaus, et al.
Publicado: (2021)

Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study
por: Hegen, Harald, et al.
Publicado: (2023)

Cerebrospinal fluid protein in Guillain–Barré syndrome: Need for age‐dependent interpretation
por: Hegen, Harald, et al.
Publicado: (2020)

Longitudinal ventricular cerebrospinal fluid profile in patients with spontaneous subarachnoid hemorrhage
por: Zinganell, Anne, et al.
Publicado: (2022)

Impairment of odor discrimination and identification is associated with disability progression and gray matter atrophy of the olfactory system in MS
por: Bsteh, Gabriel, et al.
Publicado: (2019)

Expansion of Neutrophils and Classical and Nonclassical Monocytes as a Hallmark in Relapsing-Remitting Multiple Sclerosis
por: Haschka, David, et al.
Publicado: (2020)

Utility of Two-Dimensional Difference Gel Electrophoresis in Diagnosis of Multiple Sclerosis
por: Auer, Michael, et al.
Publicado: (2018)

Diagnostic Performance of Adding the Optic Nerve Region Assessed by Optical Coherence Tomography to the Diagnostic Criteria for Multiple Sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2023)

Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders
por: Mader, Simone, et al.
Publicado: (2011)

Immune profiling in multiple sclerosis: a single-center study of 65 cytokines, chemokines, and related molecules in cerebrospinal fluid and serum
por: Berek, Klaus, et al.
Publicado: (2023)

Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi
por: Berek, Klaus, et al.
Publicado: (2020)

NMDA receptor antibodies: A rare association in inflammatory demyelinating diseases
por: Ramberger, Melanie, et al.
Publicado: (2015)

Recovery of Chronic Inflammatory Demyelinating Polyneuropathy on Treatment With Ocrelizumab in a Patient With Co-Existing Multiple Sclerosis
por: Auer, Michael, et al.
Publicado: (2022)

German translation, cultural adaptation and validation of the unidimensional self-efficacy scale for multiple sclerosis
por: Seebacher, Barbara, et al.
Publicado: (2021)

Effects of actual and imagined music-cued gait training on motor functioning and brain activity in people with multiple sclerosis: protocol of a randomised parallel multicentre trial
por: Seebacher, Barbara, et al.
Publicado: (2022)

Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis—from diagnosis to prediction of disease activity
por: Hegen, Harald, et al.
Publicado: (2022)

The clinical significance of single or double bands in cerebrospinal fluid isoelectric focusing. A retrospective study and systematic review
por: Hegen, Harald, et al.
Publicado: (2019)

‘No evidence of disease activity’ – is it an appropriate surrogate in multiple sclerosis?
por: Hegen, H., et al.
Publicado: (2018)

COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_38e30tj7f2go0ie41eg7ufkmep